UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

The New England journal of medicine, 2016-07, Vol.375 (4), p.345-356

2016

Volltextzugriff (PDF)

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

JAMA : the journal of the American Medical Association, 2009-12, Vol.302 (23), p.2557

2009

Volltextzugriff (PDF)

Sick and unsheltered: Homelessness as a major risk factor for emergency care utilization

The American journal of emergency medicine, 2019-03, Vol.37 (3), p.415-420

2019

Volltextzugriff (PDF)

Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice

Journal of investigative dermatology, 2018-09, Vol.138 (9), p.1955-1961

2018

Volltextzugriff (PDF)

Nightly treatment of primary insomnia with eszopiclone for six months : Effect on sleep, quality of life, and work limitations

Sleep (New York, N.Y.), 2007-08, Vol.30 (8), p.959-968

2007

Volltextzugriff (PDF)

Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a Randomized, double-blind, placebo-controlled study in adults with chronic insomnia

Sleep (New York, N.Y.), 2003-11, Vol.26 (7), p.793-799

2003

Volltextzugriff (PDF)

A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome

Sleep medicine, 2007-08, Vol.8 (5), p.464-470

2007

Volltextzugriff (PDF)

Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia

Current medical research and opinion, 2004-12, Vol.20 (12), p.1979-1991

2004

Volltextzugriff (PDF)

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)

Orphanet journal of rare diseases, 2015-04, Vol.10 (1), p.50, Article 50

2015

Volltextzugriff (PDF)

Dermatologists: Collaborating With Payers to Optimize Coverage Policies

Journal of drugs in dermatology, 2017-03, Vol.16 (3), p.228

2017

Volltextzugriff (PDF)

Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis

Journal of the American Academy of Dermatology, 2020-05, Vol.82 (5), p.1138-1149

2020

Volltextzugriff (PDF)

A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia

Journal of clinical sleep medicine, 2008-06, Vol.4 (3), p.229-234

2008

Volltextzugriff (PDF)

Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies

Journal of the American Academy of Dermatology, 2021-08, Vol.85 (2), p.330-336

2021

Volltextzugriff (PDF)

Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder

Biological psychiatry (1969), 2006-06, Vol.59 (11), p.1052-1060

2006

Volltextzugriff (PDF)

Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials

JAMA dermatology (Chicago, Ill.), 2016-06, Vol.152 (6), p.661

2016

Volltextzugriff (PDF)

Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3

Journal of drugs in dermatology, 2016-08, Vol.15 (8), p.958

2016

Volltextzugriff (PDF)

Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18-month international multi-center phase 3 trial

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P86-P86

2009

Volltextzugriff (PDF)

Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis

Journal of medical economics, 2017-12, Vol.20 (12), p.1224-1230

2017

Volltextzugriff (PDF)

A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia

Sleep (New York, N.Y.), 2005-06, Vol.28 (6), p.720-727

2005

Volltextzugriff (PDF)

Evaluation of the Safety and Efficacy of Ultherapy for the Treatment of Signs and Symptoms of Erythematotelangiectatic Rosacea

Skin (Milwood, N.Y.), 2017-10, Vol.1, p.s62

2017

Volltextzugriff (PDF)

Immunogenicity of idursulfase and clinical outcomes in very young patients

Orphanet journal of rare diseases, 2015-04, Vol.10

2015

Volltextzugriff (PDF)

An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults

Sleep medicine, 2005, Vol.6 (1), p.15-22

2005

Volltextzugriff (PDF)

Design Considerations for AIDS Trials

The New England journal of medicine, 1990-11, Vol.323 (19), p.1343-1348

1990

Volltextzugriff (PDF)

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa

Genetics in medicine, 2013-12, Vol.15 (12), p.983-989

2013

Volltextzugriff (PDF)

Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled, Phase 3b Clinical Trial in Patients with Moderate-to-Severe Genital Psoriasis

Skin (Milwood, N.Y.), 2018-02, Vol.2, p.S8

2018

Volltextzugriff (PDF)

1 – 25 von 1.080

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(887)
Mit Volltextzugriff
(906)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(706)
Life Sciences & Biomedicine
(516)
Humans
(381)
Female
(201)
Male
(198)
Adult
(150)
Middle Aged
(137)
Technology
(135)
Biological And Medical Sciences
(133)
Computer Science
(116)
Medical Sciences
(108)
Aged
(92)
Neurosciences & Neurology
(82)
Animals
(80)
Computer Science, Artificial Intelligence
(80)
Clinical Neurology
(74)
Robotics
(69)
Computer Science, Information Systems
(64)
Oncology
(63)
Neurosciences
(61)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta
(451)
EZB Electronic Journals Library
(442)
MEDLINE
(435)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(366)
NUS Single-Journal Subscriptions
(274)
Elsevier ScienceDirect Journals Complete
(195)
IngentaConnect Journals
(168)
Wiley Blackwell Single Titles
(102)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(101)
Oxford journals
(83)
Ebook Central Perpetual and DDA
(82)
eBooks on EBSCOhost
(82)
IEEE Electronic Library Online
(74)
Wiley Online Library
(73)
SpringerLink
(69)
Nature
(64)
Oxford Journals 2020 Medicine
(60)
JSTOR
(55)
Nexis Uni
(50)
SpringerLink Series
(38)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Fertility And Sterility
(21)
Muscle & Nerve
(18)
Neurology
(18)
Nature Genetics
(17)
Nature
(15)
Gastroenterology
(14)
Revista Da Sociedade Brasileira De Medicina Tropical
(12)
Journal Of Forestry
(11)
Forest Ecology And Management
(10)
Journal Of Clinical Oncology
(9)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

Sick and unsheltered: Homelessness as a major risk factor for emergency care utilization

Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice

Nightly treatment of primary insomnia with eszopiclone for six months : Effect on sleep, quality of life, and work limitations

Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a Randomized, double-blind, placebo-controlled study in adults with chronic insomnia

A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome

Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)

Dermatologists: Collaborating With Payers to Optimize Coverage Policies

Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis

A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia

Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies

Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder

Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials

Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3

Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18-month international multi-center phase 3 trial

Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis

A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia

Evaluation of the Safety and Efficacy of Ultherapy for the Treatment of Signs and Symptoms of Erythematotelangiectatic Rosacea

Immunogenicity of idursulfase and clinical outcomes in very young patients

An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults

Design Considerations for AIDS Trials

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa

Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled, Phase 3b Clinical Trial in Patients with Moderate-to-Severe Genital Psoriasis

Suchergebnisse filtern